Jade Biosciences, Inc.
JBIO · Nasdaq · United States
Share price · JBIO
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when JBIO's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 10 Nov 2026+5.1%
Nothing announced by JBIO that day or the session before.
- 23 Sep 2026-12.2%
Nothing announced by JBIO that day or the session before.
- 4 Aug 2026+11.5%
Nothing announced by JBIO that day or the session before.
- 23 Jun 2026+13.0%
Nothing announced by JBIO that day or the session before.
- 22 Jun 2026+15.6%
Nothing announced by JBIO that day or the session before.
- 8 Jun 2026-11.6%
Nothing announced by JBIO that day or the session before.
- 1 Jun 2026-11.6%
- 29 Apr 2026-15.6%
Nothing announced by JBIO that day or the session before.
- 22 Apr 2026+10.3%
- 16 Apr 2026+13.6%
Nothing announced by JBIO that day or the session before.
Share of unusual movement by asset
For each asset, the share of JBIO's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
| Asset | Event days | Share of unusual movement |
|---|---|---|
JADE101events and moves
| 1 | shown from 8 days |
| Assets with fewer than 8 event days, together | — | 1% |
| Other company news (earnings, financing, releases naming no asset) | — | 59% |
| Sessions with no dated event | — | 41% |
Assets
(2 total)
Upcoming events
(2 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
Financial reports
Quarterly & interim (16)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | — | $31M | $80M+ $395M short-term inv. | $35M-$29M operating cash flow | report ↗ |
View 15 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | — | $50M | $107M+ $354M short-term inv. | $56M-$44M operating cash flow | report ↗ |
| 2026-Q1 | — | $36M | $55M+ $256M short-term inv. | $40M-$24M operating cash flow | report ↗ |
| 2025-Q3 | — | $22M | $50M+ $149M short-term inv. | $25M-$22M operating cash flow | report ↗ |
| 2025-Q2 | — | $23M | $221M | $32M-$37M operating cash flow | report ↗ |
| 2025-Q1 | — | $20M | $44M+ $32M short-term inv. | $2.5M-$2.4M operating cash flow | report ↗ |
| 2024-Q3 | — | $10M | $31M+ $58M short-term inv. | $16M-$16M operating cash flow | report ↗ |
| 2024-Q2 | — | $21M | $31M+ $73M short-term inv. | $25M-$20M operating cash flow | report ↗ |
| 2024-Q1 | — | $20M | $9.1M+ $90M short-term inv. | $23M-$24M operating cash flow | report ↗ |
| 2023-Q3 | — | $17M | $32M+ $103M short-term inv. | $20M-$16M operating cash flow | report ↗ |
| 2023-Q2 | — | $16M | $61M+ $89M short-term inv. | $19M-$15M operating cash flow | report ↗ |
| 2023-Q1 | — | $13M | $27M+ $92M short-term inv. | $17M-$11M operating cash flow | report ↗ |
| 2022-Q3 | — | $11M | $22M+ $120M short-term inv. | $14M-$9.7M operating cash flow | report ↗ |
| 2022-Q2 | — | $8.4M | $27M+ $125M short-term inv. | $12M-$8.9M operating cash flow | report ↗ |
| 2022-Q1 | — | $7.3M | $28M+ $133M short-term inv. | $11M-$5.7M operating cash flow | report ↗ |
| 2021-Q3 | — | $3.4M | $181M | $6.2M-$6.5M operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | — | $93M | $88M+ $248M short-term inv. | $32M-$95M operating cash flow | report ↗ |
Jade Biosciences reported no revenue for fiscal year 2025. R&D spend was $93.12M, up 75.1% YoY; cash and equivalents were $88.44M, while total cash, cash equivalents, and investments were $336.2M as of December 31, 2025. The company reported a net loss of $127.41M for the full year.
Management guided that existing cash is expected to fund operations and capital expenditures into the first half of 2028. JADE101 Phase 1 healthy-volunteer interim data are expected in Q2 2026, with a Phase 2 trial in IgA nephropathy expected to begin mid-2026 and preliminary data anticipated in 2027. JADE201 is expected to enter a first-in-human trial in rheumatoid arthritis in Q2 2026, with interim data anticipated in 2027; JADE301 is expected to enter a Phase 1 trial in the first half of 2027. Jade also completed two private placement financings in Q4, generating gross proceeds of approximately $180M.
View 4 more years
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-FY | — | $53M | $34M+ $45M short-term inv. | $17M-$71M operating cash flow | report ↗ |
| 2023-FY | — | $64M | $23M+ $99M short-term inv. | $19M-$57M operating cash flow | report ↗ |
| 2022-FY | — | $39M | $22M+ $107M short-term inv. | $13M-$39M operating cash flow | report ↗ |
| 2021-FY | — | $15M | $54M+ $113M short-term inv. | $5.7M-$27M operating cash flow | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 0 purchases (—), 0 sales (—). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-06-25 | Eisner Mark · director | Award / grant (derivative) | 47,675 | — | — | Form 4 |
| 2026-06-09 | Fairmount Funds Management LLC; Fairmount Healthcare Fund II L.P.; Fairmount Healthcare Co-Invest IV L.P.; Kiselak Tomas; Harwin Peter Evan · director, 10% owner; director, 10% owner; director, 10% owner; director, 10% owner; director, 10% owner | Award / grant (derivative) | 34,843 | — | — | Form 4 |
| 2026-06-09 | Lavelle Erin · director | Award / grant (derivative) | 34,843 | — | — | Form 4 |
| 2026-06-09 | Klein Lawrence Otto · director | Award / grant (derivative) | 34,843 | — | — | Form 4 |
| 2026-06-09 | DOBMEIER ERIC · director | Award / grant (derivative) | 34,843 | — | — | Form 4 |
| 2026-06-09 | CAIN CHRISTOPHER W. · director | Award / grant (derivative) | 34,843 | — | — | Form 4 |
| 2026-02-12 | King Andrew James · See Remarks | Award / grant | 41,250 | — | — | Form 4 |
| 2026-02-12 | Frohlich Tom · director, Chief Executive Officer | Award / grant | 78,750 | — | — | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 120 reporting institutions held 51.4M shares ($735.7M, 74.3% of shares outstanding).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | FMR LLC | 7,085,423 | $99.6M |
| 2 | Fairmount Funds Management LLC | 4,553,494 | $64.0M |
| 3 | Avidity Partners Management LP | 2,801,416 | $53.9M |
| 4 | RA CAPITAL MANAGEMENT, L.P. | 3,671,083 | $51.6M |
| 5 | Bellevue Group AG | 3,501,502 | $49.2M |
| 6 | Venrock Adviser, LLC | 3,220,364 | $45.2M |
| 7 | JANUS HENDERSON GROUP PLC | 3,105,669 | $43.6M |
| 8 | BlackRock, Inc. | 2,313,949 | $32.5M |
| 9 | VANGUARD CAPITAL MANAGEMENT LLC | 1,796,652 | $25.2M |
| 10 | BAKER BROS. ADVISORS LP | 1,641,137 | $23.1M |
| 11 | Remedium Capital Partners, LLC | 1,577,750 | $22.2M |
| 12 | Versant Venture Management, LLC | 1,525,820 | $21.4M |
| 13 | SAMSARA BIOCAPITAL, LLC | 968,798 | $13.6M |
| 14 | GREAT POINT PARTNERS LLC | 964,462 | $13.6M |
| 15 | MARSHALL WACE, LLP | 944,776 | $13.3M |